Steven Cohen Hutchmed (China) LTD Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$16.36 - $21.78 $266,668 - $355,014	16,300 New	16,300 $279,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $185,513 - $305,115	-17,209 Reduced 63.87%	9,735 $116,000
Q1 2023 May 15, 2023	SELL	$13.02 - $19.87 $395,235 - $603,173	-30,356 Reduced 52.98%	26,944 $350,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $438,345 - $888,723	57,300 New	57,300 $846,000
Q3 2019 Nov 15, 2019	SELL	$17.84 - $22.69 $4.01 Million - $5.11 Million	-225,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $4.95 Million - $7.15 Million	225,000 New	225,000 $4.95 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.